<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB00848</drugbank-id>
  <drugbank-id>APRD01067</drugbank-id>
  <name>Levamisole</name>
  <description>Levamisole is an antihelminthic drug that was commonly used for the treatment of parasitic, viral, and bacterial infections. [A178117] It was manufactured by _Janssen_ and first used in 1969 as an agent to treat worm infestations[A178123] Levamisole was approved by the FDA in 1990 as an adjuvant treatment for colon cancer.[L6232] Prior to this, levamisole was used as an antirheumatic therapy in the 1970s and 1980s for patients with rheumatoid arthritis.[A178123] &#13;
&#13;
Because of its immunomodulatory effects, this drug has been studied in the treatment of various immune-mediated diseases, with some studies showing positive results. [A178117] This drug has also been used in combination with other drugs for the treatment of various cancers. [A178117, A178123] &#13;
&#13;
Levamisole was withdrawn from the American market in 2000 due to its ability to cause serious adverse effects, including agranulocytosis. [A178123] Interestingly, levamisole has been found as an adulterant in cocaine and can lead to a variety of adverse effects in individuals using this drug.[A178120]</description>
  <cas-number>14769-73-4</cas-number>
  <unii>2880D3468G</unii>
  <average-mass>204.291</average-mass>
  <monoisotopic-mass>204.072119084</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
    <group>vet_approved</group>
    <group>withdrawn</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A1263</ref-id>
        <pubmed-id>6203228</pubmed-id>
        <citation>Grishchenko SV, Lavrukhina LA, Ketiladze ES, Krylov VF, Ershov FI: [Results of combined therapy using levamisole for patients with influenza complicated by pneumonia]. Vopr Virusol. 1984 Mar-Apr;29(2):175-9.</citation>
      </article>
      <article>
        <ref-id>A1264</ref-id>
        <pubmed-id>1675705</pubmed-id>
        <citation>Authors unspecified: Levamisole for corticosteroid-dependent nephrotic syndrome in childhood. British Association for Paediatric Nephrology. Lancet. 1991 Jun 29;337(8757):1555-7.</citation>
      </article>
      <article>
        <ref-id>A1265</ref-id>
        <pubmed-id>6169</pubmed-id>
        <citation>Van Belle H: Alkaline phosphatase. I. Kinetics and inhibition by levamisole of purified isoenzymes from humans. Clin Chem. 1976 Jul;22(7):972-6.</citation>
      </article>
      <article>
        <ref-id>A178117</ref-id>
        <pubmed-id>15109274</pubmed-id>
        <citation>Scheinfeld N, Rosenberg JD, Weinberg JM: Levamisole in dermatology : a review. Am J Clin Dermatol. 2004;5(2):97-104. doi: 10.2165/00128071-200405020-00004.</citation>
      </article>
      <article>
        <ref-id>A178120</ref-id>
        <pubmed-id>28314885</pubmed-id>
        <citation>Brunt TM, van den Berg J, Pennings E, Venhuis B: Adverse effects of levamisole in cocaine users: a review and risk assessment. Arch Toxicol. 2017 Jun;91(6):2303-2313. doi: 10.1007/s00204-017-1947-4. Epub 2017 Mar 17.</citation>
      </article>
      <article>
        <ref-id>A178123</ref-id>
        <pubmed-id>22677078</pubmed-id>
        <citation>Lee KC, Ladizinski B, Federman DG: Complications associated with use of levamisole-contaminated cocaine: an emerging public health challenge. Mayo Clin Proc. 2012 Jun;87(6):581-6. doi: 10.1016/j.mayocp.2012.03.010.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L6232</ref-id>
        <title>FDA approval: Levamisole</title>
        <url>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=020035</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference>U.S. Patents 3,274,209; 3,364,112; 3,463,786; 3,579,530 and 3,646,051.</synthesis-reference>
  <indication>For adjuvant treatment in combination with fluorouracil after surgical resection in patients with Dukes' stage C colon cancer. Also used to treat malignant melanoma and head/neck cancer.</indication>
  <pharmacodynamics>Levamisole is a synthetic imidazothiazole derivative that has been widely used in treatment of worm infestations in both humans and animals. As an anthelmintic, it probably works by targeting the nematode nicotinergic acetylcholine receptor. As an immunomodulator, it appears that Levamisole is an immunostimulant which has been shown to increase NK cells and activated T-cells in patients receiving this adjuvantly along with 5FU for Stage III colon cancer.</pharmacodynamics>
  <mechanism-of-action>The mechanism of action of levamisole as an antiparasitic agent appears to be tied to its agnositic activity towards the L-subtype nicotinic acetylcholine receptors in nematode muscles. This agonistic action reduces the capacity of the males to control their reproductive muscles and limits their ability to copulate. The mechanism of action of Levamisole as an anticancer drug in combination with fluorouracil is unknown. The effects of levamisole on the immune system are complex. The drug appears to restore depressed immune function rather than to stimulate response to above-normal levels. Levamisole can stimulate formation of antibodies to various antigens, enhance T-cell responses by stimulating T-cell activation and proliferation, potentiate monocyte and macrophage functions including phagocytosis and chemotaxis, and increase neutrophil mobility, adherence, and chemotaxis.</mechanism-of-action>
  <toxicity>LD&lt;sub&gt;50&lt;/sub&gt; = 40 mg/kg (Pigs, subcutaneous); LD&lt;sub&gt;50&lt;/sub&gt; = 180 mg/kg (rat, oral)</toxicity>
  <metabolism>Primarily hepatic (extensive) with both active and inactive metabolites.</metabolism>
  <absorption>Levamisole is rapidly absorbed (2 hours) from the gastrointestinal tract.</absorption>
  <half-life>4.4-5.6 hours (biphasic)</half-life>
  <protein-binding>20-25%</protein-binding>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as imidazothiazoles. These are organic polycyclic compounds containing an imidazole ring fused to a thiazole ring. Imidazole is 5-membered ring consisting of three carbon atoms, and two nitrogen centers at the 1- and 3-positions. Thiazole is a 6-membered ring that contains both sulfur and nitrogen.</description>
    <direct-parent>Imidazothiazoles</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organoheterocyclic compounds</superclass>
    <class>Imidazothiazoles</class>
    <subclass/>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Benzene and substituted derivatives</alternative-parent>
    <alternative-parent>Carboximidamides</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Imidazolines</alternative-parent>
    <alternative-parent>Isothioureas</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Propargyl-type 1,3-dipolar organic compounds</alternative-parent>
    <alternative-parent>Thiazolidines</alternative-parent>
    <substituent>2-imidazoline</substituent>
    <substituent>Aromatic heteropolycyclic compound</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Benzenoid</substituent>
    <substituent>Carboximidamide</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Imidazothiazole</substituent>
    <substituent>Isothiourea</substituent>
    <substituent>Monocyclic benzene moiety</substituent>
    <substituent>Organic 1,3-dipolar compound</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Propargyl-type 1,3-dipolar organic compound</substituent>
    <substituent>Thiazolidine</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT000822</drugbank-id>
      <name>Levamisole hydrochloride</name>
      <unii>DL9055K809</unii>
      <cas-number>16595-80-5</cas-number>
      <inchikey>LAZPBGZRMVRFKY-HNCPQSOCSA-N</inchikey>
      <average-mass>240.752</average-mass>
      <monoisotopic-mass>240.048796823</monoisotopic-mass>
    </salt>
    <salt>
      <drugbank-id primary="true">DBSALT001628</drugbank-id>
      <name>Levamisole phosphate</name>
      <unii>FIG89N8AZY</unii>
      <cas-number>32093-35-9</cas-number>
      <inchikey>QEMMFDPTLWDHKP-HNCPQSOCSA-N</inchikey>
      <average-mass>302.28</average-mass>
      <monoisotopic-mass>302.049015143</monoisotopic-mass>
    </salt>
    <salt>
      <drugbank-id primary="true">DBSALT001626</drugbank-id>
      <name>Levamisole resinate</name>
      <unii/>
      <cas-number/>
      <inchikey/>
    </salt>
  </salts>
  <synonyms>
    <synonym language="spanish" coder="inn">Levamisol</synonym>
    <synonym language="english" coder="inn">Levamisole</synonym>
    <synonym language="latin" coder="inn">Levamisolum</synonym>
  </synonyms>
  <products>
    <product>
      <name>Ergamisol Tab 50mg</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00846368</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-12-31</started-marketing-on>
      <ended-marketing-on>2003-10-17</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novo-levamisole</name>
      <labeller>Novopharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02234217</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-10-17</started-marketing-on>
      <ended-marketing-on>2005-08-10</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Ergamisol</name>
      <company>Janssen</company>
    </international-brand>
    <international-brand>
      <name>Ketrax</name>
      <company>AstraZeneca</company>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Ergamisol Tab 50mg</name>
      <ingredients>Levamisole</ingredients>
    </mixture>
    <mixture>
      <name>Novo-levamisole</name>
      <ingredients>Levamisole</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Professional Co.</name>
      <url/>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Janssen pharmaceutica products lp</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Levamisole hcl powder</description>
      <cost currency="USD">7.5</cost>
      <unit>g</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Adjuvants, Immunologic</category>
      <mesh-id>D000276</mesh-id>
    </category>
    <category>
      <category>Anthelmintics</category>
      <mesh-id>D000871</mesh-id>
    </category>
    <category>
      <category>Anti-Infective Agents</category>
      <mesh-id>D000890</mesh-id>
    </category>
    <category>
      <category>Antinematodal Agents</category>
      <mesh-id>D000969</mesh-id>
    </category>
    <category>
      <category>Antiparasitic Agents</category>
      <mesh-id>D000977</mesh-id>
    </category>
    <category>
      <category>Antiparasitic Products, Insecticides and Repellents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Antirheumatic Agents</category>
      <mesh-id>D018501</mesh-id>
    </category>
    <category>
      <category>Imidazoles</category>
      <mesh-id>D007093</mesh-id>
    </category>
    <category>
      <category>Imidazothiazole Derivatives</category>
      <mesh-id/>
    </category>
    <category>
      <category>Immunologic Factors</category>
      <mesh-id>D007155</mesh-id>
    </category>
    <category>
      <category>Levamisole, analogs &amp; derivatives</category>
      <mesh-id/>
    </category>
    <category>
      <category>Sulfur Compounds</category>
      <mesh-id>D013457</mesh-id>
    </category>
    <category>
      <category>Thiazoles</category>
      <mesh-id>D013844</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="P02CE01">
      <level code="P02CE">Imidazothiazole derivatives</level>
      <level code="P02C">ANTINEMATODAL AGENTS</level>
      <level code="P02">ANTHELMINTICS</level>
      <level code="P">ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries/>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB00848.pdf?1265922744</msds>
  <patents/>
  <food-interactions>
    <food-interaction>Take on an empty stomach.</food-interaction>
  </food-interactions>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00602</drugbank-id>
      <name>Ivermectin</name>
      <description>The bioavailability of Ivermectin can be increased when combined with Levamisole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00518</drugbank-id>
      <name>Albendazole</name>
      <description>The bioavailability of Albendazole can be increased when combined with Levamisole.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>2.2</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-2.2</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>1.44e+00 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>2.36</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>(6S)-6-phenyl-2H,3H,5H,6H-imidazo[2,1-b][1,3]thiazole</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>levamisole</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>204.291</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>204.072119084</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>C1CN2C[C@@H](N=C2S1)C1=CC=CC=C1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C11H12N2S</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C11H12N2S/c1-2-4-9(5-3-1)10-8-13-6-7-14-11(13)12-10/h1-5,10H,6-8H2/t10-/m1/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>HLFSDGLLUJUHTE-SNVBAGLBSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>15.6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>60.08</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>22.35</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>6.98</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>210 mg/mL</value>
      <source/>
    </property>
    <property>
      <kind>Melting Point</kind>
      <value>227-227.5 </value>
      <source>U.S. Patents 3,274,209; 3,364,112; 3,463,786; 3,579,530 and 3,646,051.</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>1.84</value>
      <source>BIOBYTE (1995)</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>4130</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>1326</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>2363</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>2801</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>6432</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>26879</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46509052</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C07070</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D08114</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>25037</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50241179</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA450205</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000570</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Levamisole</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1454</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic3/levamisole.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/mtm/levamisole.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0003585</id>
      <name>Neuronal acetylcholine receptor subunit alpha-3</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A1713</ref-id>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <ref-id>A1715</ref-id>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <ref-id>A5745</ref-id>
            <pubmed-id>15280391</pubmed-id>
            <citation>Culetto E, Baylis HA, Richmond JE, Jones AK, Fleming JT, Squire MD, Lewis JA, Sattelle DB: The Caenorhabditis elegans unc-63 gene encodes a levamisole-sensitive nicotinic acetylcholine receptor alpha subunit. J Biol Chem. 2004 Oct 8;279(41):42476-83. Epub 2004 Jul 27.</citation>
          </article>
          <article>
            <ref-id>A5746</ref-id>
            <pubmed-id>17314321</pubmed-id>
            <citation>Rayes D, Flamini M, Hernando G, Bouzat C: Activation of single nicotinic receptor channels from Caenorhabditis elegans muscle. Mol Pharmacol. 2007 May;71(5):1407-15. Epub 2007 Feb 21.</citation>
          </article>
          <article>
            <ref-id>A5747</ref-id>
            <pubmed-id>17629760</pubmed-id>
            <citation>Parker S, Peterkin HS, Baylis HA: Muscular dystrophy associated mutations in caveolin-1 induce neurotransmission and locomotion defects in Caenorhabditis elegans. Invert Neurosci. 2007 Sep;7(3):157-64. Epub 2007 Jul 13.</citation>
          </article>
          <article>
            <ref-id>A5748</ref-id>
            <pubmed-id>19668355</pubmed-id>
            <citation>Hu Y, Xiao SH, Aroian RV: The new anthelmintic tribendimidine is an L-type (levamisole and pyrantel) nicotinic acetylcholine receptor agonist. PLoS Negl Trop Dis. 2009 Aug 11;3(8):e499. doi: 10.1371/journal.pntd.0000499.</citation>
          </article>
          <article>
            <ref-id>A1991</ref-id>
            <pubmed-id>10592235</pubmed-id>
            <citation>Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P32297" source="Swiss-Prot">
        <name>Neuronal acetylcholine receptor subunit alpha-3</name>
        <general-function>Ligand-gated ion channel activity</general-function>
        <specific-function>After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.</specific-function>
        <gene-name>CHRNA3</gene-name>
        <locus>15q24</locus>
        <cellular-location>Cell junction</cellular-location>
        <transmembrane-regions>241-265
273-291
307-328
478-497</transmembrane-regions>
        <signal-regions>1-31</signal-regions>
        <theoretical-pi>6.4</theoretical-pi>
        <molecular-weight>57479.54</molecular-weight>
        <chromosome-location>15</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1957</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M86383</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>177898</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>464</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P32297</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ACHA3_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>NACHRA3</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0006903|Neuronal acetylcholine receptor subunit alpha-3
MGSGPLSLPLALSPPRLLLLLLLSLLPVARASEAEHRLFERLFEDYNEIIRPVANVSDPV
IIHFEVSMSQLVKVDEVNQIMETNLWLKQIWNDYKLKWNPSDYGGAEFMRVPAQKIWKPD
IVLYNNAVGDFQVDDKTKALLKYTGEVTWIPPAIFKSSCKIDVTYFPFDYQNCTMKFGSW
SYDKAKIDLVLIGSSMNLKDYWESGEWAIIKAPGYKHDIKYNCCEEIYPDITYSLYIRRL
PLFYTINLIIPCLLISFLTVLVFYLPSDCGEKVTLCISVLLSLTVFLLVITETIPSTSLV
IPLIGEYLLFTMIFVTLSIVITVFVLNVHYRTPTTHTMPSWVKTVFLNLLPRVMFMTRPT
SNEGNAQKPRPLYGAELSNLNCFSRAESKGCKEGYPCQDGMCGYCHHRRIKISNFSANLT
RSSSSESVDAVLSLSALSPEIKEAIQSVKYIAENMKAQNEAKEIQDDWKYVAMVIDRIFL
WVFTLVCILGTAGLFLQPLMAREDA</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012491|Neuronal acetylcholine receptor subunit alpha-3 (CHRNA3)
ATGGGCTCTGGCCCGCTCTCGCTGCCCCTGGCGCTGTCGCCGCCGCGGCTGCTGCTGCTG
CTGCTGCTGTCTCTGCTGCCAGTGGCCAGGGCCTCAGAGGCTGAGCACCGTCTATTTGAG
CGGCTGTTTGAAGATTACAATGAGATCATCCGGCCTGTAGCCAACGTGTCTGACCCAGTC
ATCATCCATTTCGAGGTGTCCATGTCTCAGCTGGTGAAGGTGGATGAAGTAAACCAGATC
ATGGAGACCAACCTGTGGCTCAAGCAAATCTGGAATGACTACAAGCTGAAATGGAACCCC
TCTGACTATGGTGGGGCAGAGTTCATGCGTGTCCCTGCACAGAAGATCTGGAAGCCAGAC
ATTGTGCTGTATAACAATGCTGTTGGGGATTTCCAGGTGGACGACAAGACCAAAGCCTTA
CTCAAGTACACTGGGGAGGTGACTTGGATACCTCCGGCCATCTTTAAGAGCTCCTGTAAA
ATCGACGTGACCTACTTCCCGTTTGATTACCAAAACTGTACCATGAAGTTCGGTTCCTGG
TCCTACGATAAGGCGAAAATCGATCTGGTCCTGATCGGCTCTTCCATGAACCTCAAGGAC
TATTGGGAGAGCGGCGAGTGGGCCATCATCAAAGCCCCAGGCTACAAACACGACATCAAG
TACAACTGCTGCGAGGAGATCTACCCCGACATCACATACTCGCTGTACATCCGGCGCCTG
CCCTTGTTCTACACCATCAACCTCATCATCCCCTGCCTGCTCATCTCCTTCCTCACTGTG
CTCGTCTTCTACCTGCCCTCCGACTGCGGTGAGAAGGTGACCCTGTGCATTTCTGTCCTC
CTCTCCCTGACGGTGTTTCTCCTGGTGATCACTGAGACCATCCCTTCCACCTCGCTGGTC
ATCCCCCTGATTGGAGAGTACCTCCTGTTCACCATGATTTTTGTAACCTTGTCCATCGTC
ATCACCGTCTTCGTGCTCAACGTGCACTACAGAACCCCGACGACACACACAATGCCCTCA
TGGGTGAAGACTGTATTCTTGAACCTGCTCCCCAGGGTCATGTTCATGACCAGGCCAACA
AGCAACGAGGGCAACGCTCAGAAGCCGAGGCCCCTCTACGGTGCCGAGCTCTCAAATCTG
AATTGCTTCAGCCGCGCAGAGTCCAAAGGCTGCAAGGAGGGCTACCCCTGCCAGGACGGG
ATGTGTGGTTACTGCCACCACCGCAGGATAAAAATCTCCAATTTCAGTGCTAACCTCACG
AGAAGCTCTAGTTCTGAATCTGTTGATGCTGTGCTGTCCCTCTCTGCTTTGTCACCAGAA
ATCAAAGAAGCCATCCAAAGTGTCAAGTATATTGCTGAAAATATGAAAGCACAAAATGAA
GCCAAAGAGATTCAAGATGATTGGAAGTATGTTGCCATGGTGATTGATCGTATTTTTCTG
TGGGTTTTCACCCTGGTGTGCATTCTAGGGACAGCAGGATTGTTTCTGCAACCCCTGATG
GCCAGGGAAGATGCATAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF02931</identifier>
            <name>Neur_chan_LBD</name>
          </pfam>
          <pfam>
            <identifier>PF02932</identifier>
            <name>Neur_chan_memb</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>acetylcholine-gated channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendrite</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuron projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal cell body</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic density</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synapse</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>acetylcholine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>acetylcholine receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>acetylcholine-activated cation-selective channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ligand-gated ion channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of transmembrane receptor protein tyrosine kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>behavioral response to nicotine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cation transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>excitatory postsynaptic potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heart development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>locomotory behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nervous system development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurological system process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein heterooligomerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of acetylcholine secretion, neurotransmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of dendrite morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of membrane potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of smooth muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to inorganic substance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission involved in micturition</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission, cholinergic</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="2">
      <id>BE0000896</id>
      <name>Alkaline phosphatase, placental-like</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A12149</ref-id>
            <pubmed-id>10951365</pubmed-id>
            <citation>Chang YL, Stanford CM, Keller JC: Calcium and phosphate supplementation promotes bone cell mineralization: implications for hydroxyapatite (HA)-enhanced bone formation. J Biomed Mater Res. 2000 Nov;52(2):270-8.</citation>
          </article>
          <article>
            <ref-id>A12150</ref-id>
            <pubmed-id>11304750</pubmed-id>
            <citation>Funk CJ: Alkaline phosphatase activity in whitefly salivary glands and saliva. Arch Insect Biochem Physiol. 2001 Apr;46(4):165-74.</citation>
          </article>
          <article>
            <ref-id>A12151</ref-id>
            <pubmed-id>11403767</pubmed-id>
            <citation>de Aguiar Matos JA, Borges FP, Tasca T, Bogo MR, De Carli GA, da Graca Fauth M, Dias RD, Bonan CD: Characterisation of an ATP diphosphohydrolase (Apyrase, EC 3.6.1.5) activity in Trichomonas vaginalis. Int J Parasitol. 2001 Jun;31(8):770-5.</citation>
          </article>
          <article>
            <ref-id>A12152</ref-id>
            <pubmed-id>11850443</pubmed-id>
            <citation>McDougall K, Plumb C, King WA, Hahnel A: Inhibitor profiles of alkaline phosphatases in bovine preattachment embryos and adult tissues. J Histochem Cytochem. 2002 Mar;50(3):415-22.</citation>
          </article>
          <article>
            <ref-id>A12153</ref-id>
            <pubmed-id>12615144</pubmed-id>
            <citation>Soory M, Suchak A: Effects of alkaline phosphatase and its inhibitor levamisole on the modulation of androgen metabolism by nicotine and minocycline in human gingival and oral periosteal fibroblasts. Arch Oral Biol. 2003 Jan;48(1):69-76.</citation>
          </article>
          <article>
            <ref-id>A12154</ref-id>
            <pubmed-id>18719742</pubmed-id>
            <citation>Mota A, Silva P, Neves D, Lemos C, Calhau C, Torres D, Martel F, Fraga H, Ribeiro L, Alcada MN, Pinho MJ, Negrao MR, Pedrosa R, Guerreiro S, Guimaraes JT, Azevedo I, Martins MJ: Characterization of rat heart alkaline phosphatase isoenzymes and modulation of activity. Braz J Med Biol Res. 2008 Jul;41(7):600-9.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P10696" source="Swiss-Prot">
        <name>Alkaline phosphatase, placental-like</name>
        <general-function>Metal ion binding</general-function>
        <specific-function/>
        <gene-name>ALPPL2</gene-name>
        <locus>2q37</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-19</signal-regions>
        <theoretical-pi>6.31</theoretical-pi>
        <molecular-weight>57376.515</molecular-weight>
        <chromosome-location>2</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:441</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ALPPL2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>J03252</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>178428</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P10696</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PPBN_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.1.3.1</synonym>
          <synonym>Alkaline phosphatase Nagao isozyme</synonym>
          <synonym>ALP-1</synonym>
          <synonym>ALPPL</synonym>
          <synonym>GCAP</synonym>
          <synonym>Germ cell alkaline phosphatase</synonym>
          <synonym>Placental alkaline phosphatase-like</synonym>
          <synonym>PLAP-like</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001786|Alkaline phosphatase, placental-like
MQGPWVLLLLGLRLQLSLGIIPVEEENPDFWNRQAAEALGAAKKLQPAQTAAKNLIIFLG
DGMGVSTVTAARILKGQKKDKLGPETFLAMDRFPYVALSKTYSVDKHVPDSGATATAYLC
GVKGNFQTIGLSAAARFNQCNTTRGNEVISVMNRAKKAGKSVGVVTTTRVQHASPAGAYA
HTVNRNWYSDADVPASARQEGCQDIATQLISNMDIDVILGGGRKYMFPMGTPDPEYPDDY
SQGGTRLDGKNLVQEWLAKHQGARYVWNRTELLQASLDPSVTHLMGLFEPGDMKYEIHRD
STLDPSLMEMTEAALLLLSRNPRGFFLFVEGGRIDHGHHESRAYRALTETIMFDDAIERA
GQLTSEEDTLSLVTADHSHVFSFGGYPLRGSSIFGLAPGKARDRKAYTVLLYGNGPGYVL
KDGARPDVTESESGSPEYRQQSAVPLDGETHAGEDVAVFARGPQAHLVHGVQEQTFIAHV
MAFAACLEPYTACDLAPRAGTTDAAHPGPSVVPALLPLLAGTLLLLGTATAP</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010631|Alkaline phosphatase, placental-like (ALPPL2)
ATGCAGGGGCCCTGGGTGCTGCTCCTGCTGGGCCTGAGGCTACAGCTCTCCCTGGGCATC
ATCCCAGTTGAGGAGGAGAACCCGGACTTCTGGAACCGCCAGGCAGCCGAGGCCCTGGGT
GCCGCCAAGAAGCTGCAGCCTGCACAGACAGCCGCCAAGAACCTCATCATCTTCCTGGGT
GACGGGATGGGGGTGTCTACGGTGACAGCTGCCAGGATCCTAAAAGGGCAGAAGAAGGAC
AAACTGGGGCCTGAGACCTTCCTGGCCATGGACCGCTTCCCGTACGTGGCTCTGTCCAAG
ACATACAGTGTAGACAAGCATGTGCCAGACAGTGGAGCCACAGCCACGGCCTACCTGTGC
GGGGTCAAGGGCAACTTCCAGACCATTGGCTTGAGTGCAGCCGCCCGCTTTAACCAGTGC
AACACGACACGCGGCAACGAGGTCATCTCCGTGATGAATCGGGCCAAGAAAGCAGGAAAG
TCAGTGGGAGTGGTAACCACCACACGGGTGCAGCATGCCTCGCCAGCCGGCGCCTACGCC
CACACGGTGAACCGCAACTGGTACTCGGATGCCGACGTGCCTGCCTCGGCCCGCCAGGAG
GGGTGCCAGGACATCGCCACGCAGCTCATCTCCAACATGGACATTGATGTGATCCTAGGT
GGAGGCCGAAAGTACATGTTTCCCATGGGGACCCCAGACCCTGAGTACCCAGATGACTAC
AGCCAAGGTGGGACCAGGCTGGACGGGAAGAATCTGGTGCAGGAATGGCTGGCGAAGCAC
CAGGGTGCCCGGTACGTGTGGAACCGCACTGAGCTCCTGCAGGCTTCCCTGGACCCGTCT
GTGACCCATCTCATGGGTCTCTTTGAGCCTGGAGACATGAAATACGAGATCCACCGAGAC
TCCACACTGGACCCCTCCCTGATGGAGATGACAGAGGCTGCCCTGCTCCTGCTGAGCAGG
AACCCCCGCGGCTTCTTCCTCTTCGTGGAGGGTGGTCGCATCGACCATGGTCATCATGAA
AGCAGGGCTTACCGGGCACTGACTGAGACGATCATGTTCGACGACGCCATTGAGAGGGCG
GGCCAGCTCACCAGCGAGGAGGACACGCTGAGCCTCGTCACTGCCGACCACTCCCACGTC
TTCTCCTTCGGAGGCTACCCCCTGCGAGGGAGCTCCATCTTCGGGCTGGCCCCTGGCAAG
GCCCGGGACAGGAAGGCCTACACGGTCCTCCTATACGGAAACGGTCCAGGCTATGTGCTC
AAGGACGGCGCCCGGCCGGATGTTACGGAGAGCGAGAGCGGGAGCCCCGAGTATCGGCAG
CAGTCAGCAGTGCCCCTGGACGGAGAGACCCACGCAGGCGAGGACGTGGCGGTGTTCGCG
CGCGGCCCGCAGGCGCACCTGGTTCACGGCGTGCAGGAGCAGACCTTCATAGCGCACGTC
ATGGCCTTCGCCGCCTGCCTGGAGCCCTACACCGCCTGCGACCTGGCGCCCCGCGCCGGC
ACCACCGACGCCGCGCACCCGGGGCCGTCCGTGGTCCCCGCGTTGCTTCCTCTGCTGGCA
GGGACCTTGCTGCTGCTGGGGACGGCCACTGCTCCCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00245</identifier>
            <name>Alk_phosphatase</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>anchored component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>alkaline phosphatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dephosphorylation</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="3">
      <id>BE0004925</id>
      <name>Acetylcholine receptor subunit alpha-type unc-38</name>
      <organism>Caenorhabditis elegans</organism>
      <actions>
        <action>activator</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A5745</ref-id>
            <pubmed-id>15280391</pubmed-id>
            <citation>Culetto E, Baylis HA, Richmond JE, Jones AK, Fleming JT, Squire MD, Lewis JA, Sattelle DB: The Caenorhabditis elegans unc-63 gene encodes a levamisole-sensitive nicotinic acetylcholine receptor alpha subunit. J Biol Chem. 2004 Oct 8;279(41):42476-83. Epub 2004 Jul 27.</citation>
          </article>
          <article>
            <ref-id>A5746</ref-id>
            <pubmed-id>17314321</pubmed-id>
            <citation>Rayes D, Flamini M, Hernando G, Bouzat C: Activation of single nicotinic receptor channels from Caenorhabditis elegans muscle. Mol Pharmacol. 2007 May;71(5):1407-15. Epub 2007 Feb 21.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q23022" source="Swiss-Prot">
        <name>Acetylcholine receptor subunit alpha-type unc-38</name>
        <general-function>Acetylcholine-activated cation-selective channel activity</general-function>
        <specific-function>Acetylcholine receptor.</specific-function>
        <gene-name>unc-38</gene-name>
        <locus/>
        <cellular-location>Cell junction</cellular-location>
        <transmembrane-regions>262-282
291-311
324-344
465-485</transmembrane-regions>
        <signal-regions>1-16</signal-regions>
        <theoretical-pi/>
        <molecular-weight>59453.83</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="6239">Caenorhabditis elegans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q23022</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ACH5_CAEEL</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Uncoordinated protein 38</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0021413|Acetylcholine receptor subunit alpha-type unc-38
MRSFWLFLLLLLFCISFIKLTEGNEDAKRLYDDLMVNYNRHRRPSTSPNKPLTIKLKLRL
SQIIDVHEIDQIMTCSVWLKQTWIDRKLSWDPVNYGGVNVLYVPYEMIWVPDIVLYNNAD
SNYNITISTKATLHYTGEVTWEPPAIFKSMCQIDVRWFPFDEQQCHLKFGSWTFSENLLS
VELNEPSLRYEEEIDEKGIIDNVTVAEDGIDLSDYYPSVEWDIMSRVAKRRAKNYPSCCP
QSAYIDVTYYLQLRRKPLFYTVNLVFPCVGISFLTILVFYLPSDSGEKVTLCISILVALT
IFFLLLTEIIPATSITLPLIGKYLLFTMVMVTLSVVVTVISLNLHFRTPTTHLMPNWVKK
VFLKWLPKLLFMRRPIDDYEEKFDDKKKPKDGKIALSVHAHRVSNVGNNIRNATIDDTIQ
KMYYSPPVVKAFENICFIAELLKKKDRDDKIDEDWKYVAMVLDRLFLLIFSIACFVGTVI
ILLRAPTLYDTRQPIDLQYRPANLSANPISF</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021414|Acetylcholine receptor subunit alpha-type unc-38 (unc-38)
ATGCGCTCTTTTTGGTTATTCCTTTTACTGTTATTATTTTGCATCTCATTTATTAAATTA
ACCGAAGGAAATGAAGATGCTAAACGGCTTTATGATGATCTCATGGTTAATTATAATCGG
CACAGGAGGCCGTCTACATCACCGAACAAGCCATTGACAATAAAGCTGAAACTCCGCCTC
AGTCAGATTATCGATGTGCACGAGATTGATCAGATTATGACGTGTTCGGTTTGGTTAAAA
CAGACATGGATTGACAGAAAACTCTCATGGGATCCAGTGAATTATGGGGGTGTAAATGTA
TTATATGTTCCTTATGAAATGATTTGGGTACCGGATATTGTCCTGTACAATAACGCTGAC
AGCAACTACAACATCACAATTTCAACAAAAGCAACACTTCATTACACTGGAGAAGTTACC
TGGGAGCCACCAGCAATCTTCAAGAGTATGTGTCAAATTGATGTAAGATGGTTCCCGTTT
GATGAGCAACAATGCCATTTGAAGTTCGGCTCCTGGACATTTTCTGAAAATCTGCTCTCC
GTGGAATTGAACGAACCAAGTCTCCGATACGAAGAAGAAATTGACGAAAAGGGGATAATA
GACAATGTAACTGTTGCCGAAGATGGAATTGATTTATCCGATTATTATCCATCTGTCGAA
TGGGATATTATGTCAAGAGTTGCCAAAAGAAGAGCAAAGAACTATCCAAGTTGTTGTCCA
CAGAGTGCTTATATTGATGTTACTTATTACCTCCAACTCCGCCGTAAACCGCTCTTCTAC
ACAGTCAATCTGGTCTTCCCATGTGTCGGGATCTCATTTCTCACAATTCTTGTATTCTAT
CTTCCATCGGATTCTGGAGAGAAAGTGACACTTTGTATATCAATTCTTGTCGCCTTGACT
ATCTTCTTCTTGCTGCTCACTGAAATCATTCCGGCCACATCGATCACGTTGCCACTGATT
GGAAAATATCTACTGTTCACAATGGTGATGGTTACACTTTCTGTCGTGGTTACTGTTATT
TCATTAAACTTGCATTTCCGTACTCCAACAACCCATTTGATGCCTAATTGGGTGAAGAAA
GTATTCCTAAAATGGCTTCCAAAACTTCTTTTCATGAGACGACCAATCGATGATTACGAG
GAAAAATTCGATGATAAAAAGAAGCCGAAAGACGGGAAAATTGCATTGAGCGTTCATGCA
CATCGAGTTTCAAATGTTGGAAATAACATTAGGAATGCAACAATTGATGACACAATTCAA
AAAATGTATTATTCTCCGCCAGTTGTAAAAGCTTTCGAAAATATTTGCTTTATCGCCGAA
CTGCTGAAAAAGAAAGATCGAGACGATAAAATCGATGAGGATTGGAAATACGTGGCAATG
GTCCTTGATCGACTTTTCCTTCTTATTTTCTCAATTGCTTGTTTTGTAGGAACAGTTATA
ATTCTTTTGAGGGCACCAACACTGTATGACACACGACAACCCATCGATTTGCAGTATCGT
CCAGCCAATTTATCTGCTAATCCAATTAGTTTCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF02931</identifier>
            <name>Neur_chan_LBD</name>
          </pfam>
          <pfam>
            <identifier>PF02932</identifier>
            <name>Neur_chan_memb</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>acetylcholine-gated channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuron projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synapse</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>acetylcholine-activated cation-selective channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion import across plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cation transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inorganic cation transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>locomotion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurological system process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuromuscular synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of membrane potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of oviposition</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to nicotine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission, cholinergic</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="4">
      <id>BE0004926</id>
      <name>Acetylcholine receptor subunit alpha-type unc-63</name>
      <organism>Caenorhabditis elegans</organism>
      <actions>
        <action>activator</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A5745</ref-id>
            <pubmed-id>15280391</pubmed-id>
            <citation>Culetto E, Baylis HA, Richmond JE, Jones AK, Fleming JT, Squire MD, Lewis JA, Sattelle DB: The Caenorhabditis elegans unc-63 gene encodes a levamisole-sensitive nicotinic acetylcholine receptor alpha subunit. J Biol Chem. 2004 Oct 8;279(41):42476-83. Epub 2004 Jul 27.</citation>
          </article>
          <article>
            <ref-id>A5746</ref-id>
            <pubmed-id>17314321</pubmed-id>
            <citation>Rayes D, Flamini M, Hernando G, Bouzat C: Activation of single nicotinic receptor channels from Caenorhabditis elegans muscle. Mol Pharmacol. 2007 May;71(5):1407-15. Epub 2007 Feb 21.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q9N587" source="Swiss-Prot">
        <name>Acetylcholine receptor subunit alpha-type unc-63</name>
        <general-function>Acetylcholine-gated cation channel activity</general-function>
        <specific-function>Acetylcholine receptor.</specific-function>
        <gene-name>unc-63</gene-name>
        <locus/>
        <cellular-location>Cell junction</cellular-location>
        <transmembrane-regions>264-284
293-313
326-346
471-491</transmembrane-regions>
        <signal-regions>1-23</signal-regions>
        <theoretical-pi/>
        <molecular-weight>57390.645</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="6239">Caenorhabditis elegans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9N587</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ACH6_CAEEL</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>lev-7</synonym>
          <synonym>Levamisole-resistant protein 7</synonym>
          <synonym>Uncoordinated protein 63</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0013366|Acetylcholine receptor subunit alpha-type unc-63
MGPNDHGFAYILIFLLLSPPTHANRDANRLFEDLIADYNKLVRPVSENGETLVVTFKLKL
SQLLDVHEKNQIMTTNVWLQHSWMDYKLRWDPVEYGGVEVLYVPSDTIWLPDVVLYNNAD
GNYQVTIMTKAKLTYNGTVEWAPPAIYKSMCQIDVEFFPFDRQQCEMKFGSWTYGGLEVD
LQHRDKHLEKEIEEDVEGVDGPTKEIVWVVDRGIDLSDYYPSVEWDILNVPGKRHSKRYP
CCESPFIDITYEIHLRRKTLFYTVNLIFPSVGISFLTALVFYLPSDGGEKISLCISILIS
LTVFFLLLVEIIPSTSLVIPLIGKYLLFTMVLVTLSVVVTVVTLNVHYRSPTTHTMPKWM
KRLFVDFLPKYLLMTRPQPPGHHSKPNRKFDSRASTFSIGVNHVLGQNSELLSPGLNSNR
EESSFTLPRDNSPVRSAVESVAYIADHLKNEEDDKQVIEDWKYISVVMDRIFLITFTFAC
AFGTVVIIARAPSIYDNTPALA</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0013367|Acetylcholine receptor subunit alpha-type unc-63 (unc-63)
ATGGGACCAAATGACCACGGTTTTGCGTACATCCTCATATTTCTGCTCCTCTCTCCACCA
ACACATGCGAACAGAGATGCGAATCGGTTATTTGAGGATCTTATCGCAGATTACAATAAA
CTGGTGCGACCGGTCAGTGAAAACGGAGAGACACTCGTGGTGACGTTCAAATTAAAATTA
AGTCAATTATTAGATGTTCATGAAAAGAATCAGATTATGACAACAAATGTCTGGTTACAA
CATAGCTGGATGGACTACAAACTTCGATGGGATCCAGTAGAATATGGTGGTGTAGAAGTA
CTGTATGTTCCATCAGATACCATTTGGCTACCTGACGTTGTTTTATATAATAATGCCGAT
GGAAATTATCAAGTTACAATTATGACAAAAGCAAAGCTGACATATAATGGAACAGTTGAA
TGGGCACCGCCTGCGATCTATAAAAGCATGTGCCAAATCGACGTTGAATTCTTTCCATTT
GACCGTCAACAATGTGAAATGAAATTTGGATCATGGACATATGGAGGATTAGAAGTTGAT
CTACAACATAGAGACAAACATTTGGAAAAAGAAATTGAAGAAGACGTTGAAGGTGTTGAT
GGCCCAACAAAAGAAATTGTATGGGTTGTTGATAGAGGAATTGATTTAAGTGATTATTAT
CCATCTGTCGAATGGGATATTTTAAATGTTCCCGGAAAAAGGCATTCCAAGCGATACCCA
TGTTGCGAAAGTCCATTCATAGACATCACATACGAGATTCATCTTCGAAGGAAAACGTTA
TTCTACACAGTAAATCTAATATTCCCTTCAGTTGGAATCAGTTTTCTCACGGCACTTGTA
TTCTATCTACCATCGGATGGAGGTGAAAAAATCTCACTTTGTATTTCGATTCTTATCTCG
TTGACTGTTTTCTTCCTTCTGCTCGTAGAGATTATTCCATCAACATCACTTGTGATTCCA
TTAATTGGAAAATATCTTCTATTTACAATGGTTCTTGTCACATTATCTGTGGTGGTTACT
GTAGTTACATTGAATGTACATTATCGATCCCCAACAACACATACAATGCCAAAATGGATG
AAGCGGTTATTCGTGGATTTTCTGCCAAAATATCTTCTCATGACACGACCGCAACCTCCT
GGTCATCATAGCAAACCAAATCGGAAGTTCGACTCCCGTGCATCAACATTCAGTATTGGA
GTGAATCATGTATTGGGACAGAATTCTGAATTATTATCACCAGGACTCAATTCCAATAGG
GAAGAGTCTTCATTTACTTTACCACGCGACAACTCGCCAGTTCGATCTGCTGTCGAAAGT
GTTGCCTATATAGCGGATCATTTGAAAAACGAGGAAGATGATAAACAGGTAATCGAGGAC
TGGAAATACATATCAGTCGTCATGGATCGAATATTTTTAATCACATTCACTTTTGCTTGT
GCTTTTGGAACCGTTGTGATTATTGCACGTGCACCGTCCATTTACGATAACACGCCGGCT
CTTGCTTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF02931</identifier>
            <name>Neur_chan_LBD</name>
          </pfam>
          <pfam>
            <identifier>PF02932</identifier>
            <name>Neur_chan_memb</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>acetylcholine-gated channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuromuscular junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuron projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>acetylcholine-activated cation-selective channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>acetylcholine-gated cation channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion import across plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cation transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>locomotion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurological system process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuromuscular synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>post-embryonic development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of locomotion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of membrane potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of oviposition</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to nicotine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission, cholinergic</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="5">
      <id>BE0004927</id>
      <name>Acetylcholine receptor subunit beta-type lev-1</name>
      <organism>Caenorhabditis elegans</organism>
      <actions>
        <action>activator</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A5745</ref-id>
            <pubmed-id>15280391</pubmed-id>
            <citation>Culetto E, Baylis HA, Richmond JE, Jones AK, Fleming JT, Squire MD, Lewis JA, Sattelle DB: The Caenorhabditis elegans unc-63 gene encodes a levamisole-sensitive nicotinic acetylcholine receptor alpha subunit. J Biol Chem. 2004 Oct 8;279(41):42476-83. Epub 2004 Jul 27.</citation>
          </article>
          <article>
            <ref-id>A5746</ref-id>
            <pubmed-id>17314321</pubmed-id>
            <citation>Rayes D, Flamini M, Hernando G, Bouzat C: Activation of single nicotinic receptor channels from Caenorhabditis elegans muscle. Mol Pharmacol. 2007 May;71(5):1407-15. Epub 2007 Feb 21.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q27218" source="Swiss-Prot">
        <name>Acetylcholine receptor subunit beta-type lev-1</name>
        <general-function>Acetylcholine-activated cation-selective channel activity</general-function>
        <specific-function>Acetylcholine receptor.</specific-function>
        <gene-name>lev-1</gene-name>
        <locus/>
        <cellular-location>Cell junction</cellular-location>
        <transmembrane-regions>139-159
243-263
271-291
305-325
454-474</transmembrane-regions>
        <signal-regions>1-31</signal-regions>
        <theoretical-pi/>
        <molecular-weight>58025.88</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="6239">Caenorhabditis elegans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q27218</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ACH7_CAEEL</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Levamisole-resistant protein 1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0017564|Acetylcholine receptor subunit beta-type lev-1
MMLGGGGGCGAGGTWLGFLVFLAVSLRNHSTCEDIDAEDRLMVDLFRGYNSLVQPVRNRS
ELPMIVKIGMQLVLLINVDEKEQVMHTNVWLTMKWDDFQLKWDPRDYANITQIRVAPEKV
WLPDIVLFNNADGNYEVSFMCNVLILSTGTVLWVPPAIYKSSCIIDVEFFPFDDQLCSLT
FGSWTYNRDEIKLDFLTSDRVDFSEYSTSSIWDMMDGPAVLTSDRSRIEFQIRIRRKTLF
YTVVLILPTVLMAFLNVTVFYLPTASGEKMGLTMNVLLSIVVFLLLVSKILPPTSSSIPL
VAKYLLLTFVLNIITIMVTTIICNIYFRSPITHRLPPWVRKVFLDILPLLMCMQRPHRKN
VIQRSHRRLLETGPSVEENPMRSGEHHPLCRHTHNQDSCRRVRIQSDELDDELSPEAQRA
IDAIEFITENRRDEEITKQFRDDWKFIASVVDRFLLYGFFGATVGGTIGIIFTAPSVFET
FDENATLVKLKQLYDMGLANDTVLGIF</amino-acid-sequence>
        <gene-sequence format="FASTA"/>
        <pfams>
          <pfam>
            <identifier>PF02931</identifier>
            <name>Neur_chan_LBD</name>
          </pfam>
          <pfam>
            <identifier>PF02932</identifier>
            <name>Neur_chan_memb</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>acetylcholine-gated channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuron projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal cell body</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>acetylcholine-activated cation-selective channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cation transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inorganic cation transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurological system process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuromuscular synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of locomotion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of membrane potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of oviposition</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to nicotine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission, cholinergic</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="6">
      <id>BE0004928</id>
      <name>Acetylcholine receptor subunit beta-type unc-29</name>
      <organism>Caenorhabditis elegans</organism>
      <actions>
        <action>activator</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A5745</ref-id>
            <pubmed-id>15280391</pubmed-id>
            <citation>Culetto E, Baylis HA, Richmond JE, Jones AK, Fleming JT, Squire MD, Lewis JA, Sattelle DB: The Caenorhabditis elegans unc-63 gene encodes a levamisole-sensitive nicotinic acetylcholine receptor alpha subunit. J Biol Chem. 2004 Oct 8;279(41):42476-83. Epub 2004 Jul 27.</citation>
          </article>
          <article>
            <ref-id>A5746</ref-id>
            <pubmed-id>17314321</pubmed-id>
            <citation>Rayes D, Flamini M, Hernando G, Bouzat C: Activation of single nicotinic receptor channels from Caenorhabditis elegans muscle. Mol Pharmacol. 2007 May;71(5):1407-15. Epub 2007 Feb 21.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P48181" source="Swiss-Prot">
        <name>Acetylcholine receptor subunit beta-type unc-29</name>
        <general-function>Acetylcholine-activated cation-selective channel activity</general-function>
        <specific-function>Acetylcholine receptor.</specific-function>
        <gene-name>unc-29</gene-name>
        <locus/>
        <cellular-location>Cell junction</cellular-location>
        <transmembrane-regions>233-254
262-280
296-317
446-466</transmembrane-regions>
        <signal-regions>1-26</signal-regions>
        <theoretical-pi/>
        <molecular-weight>56496.52</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="6239">Caenorhabditis elegans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P48181</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ACH2_CAEEL</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Uncoordinated protein 29</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0020815|Acetylcholine receptor subunit beta-type unc-29
MRTNRLSWILVLSVVIFLVIINTINASDDEERLMVDVFRGYNSLIQPVRNSSELPLIVKM
ALQLVLLINVDEKDQVMHTNVWLTLQWHDFQMKWNPVNYGEIKQIRVSPDKVWLPDIVLF
NNADGNYEVSFMCNVVINHKGDMLWVPPAIYKSSCIIDVEFFPFDEQVCTLVFGSWTYNE
NEIKLEFVQAELVDVSEYSASSIWDVIDVPASLVNKRSRIEFQVRIRRKTLFYTVVLIIP
TVLMAFLSMAVFFLPTDSGEKITLTISVLLSIVVFLLLVSKILPPTSSTIPLMAKYLLLT
FVLNVITILVTVIIINVYFRGPRTHRMPQWVRVVFLQFLPKLVCMKRPKSASERSAVRSG
MAQLPGVGQFTLSPSAHHPLCPSADDRTTTIRNTASNETSAYYPLSTDALRAIDAIEYIT
EHLKRDEQHKSFRDDWKYVAMIIDRLLLYVFFGITVGGTCGILFSAPHVFQRIDQQEMLD
RLKEKYDTASNIP</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020816|Acetylcholine receptor subunit beta-type unc-29 (unc-29)
ATGAGGACCAACCGACTATCATGGATTTTGGTACTAAGTGTAGTTATATTTCTTGTAATA
ATAAATACCATAAACGCATCGGATGATGAAGAACGATTGATGGTGGATGTATTTCGAGGC
TATAATTCTCTCATTCAGCCAGTCCGAAATTCGTCTGAACTTCCATTAATTGTCAAAATG
GCTCTGCAGTTGGTGTTGCTCATCAATGTGGACGAGAAAGATCAAGTTATGCATACAAAT
GTTTGGCTTACGCTGCAGTGGCATGATTTTCAAATGAAATGGAACCCTGTCAACTACGGA
GAAATCAAACAAATTCGAGTGTCACCAGATAAAGTTTGGCTCCCTGACATAGTTTTGTTC
AACAATGCCGATGGAAATTACGAGGTGTCATTTATGTGTAATGTAGTTATTAATCACAAA
GGAGATATGTTATGGGTTCCGCCGGCAATTTATAAAAGCAGCTGTATCATTGACGTCGAA
TTCTTCCCATTTGATGAACAAGTGTGCACTTTGGTATTTGGAAGTTGGACTTATAACGAA
AACGAAATAAAACTGGAATTTGTTCAAGCCGAACTTGTAGATGTCTCTGAATATTCAGCA
AGCTCAATTTGGGATGTTATAGATGTTCCAGCATCATTGGTCAATAAGAGATCGAGAATT
GAATTTCAAGTTCGAATTCGTCGAAAGACACTTTTTTACACTGTTGTCCTAATTATTCCA
ACGGTTTTAATGGCATTCTTGAGTATGGCTGTATTTTTCTTGCCTACTGATTCTGGAGAA
AAAATAACGTTGACAATATCTGTTCTACTCTCCATCGTTGTGTTCTTGCTTCTTGTATCA
AAGATTCTTCCACCAACATCTTCTACAATTCCATTGATGGCCAAATATCTACTGTTGACA
TTTGTTCTTAATGTTATCACAATTCTAGTTACTGTCATCATTATCAATGTATATTTCCGA
GGACCAAGAACTCATCGGATGCCACAATGGGTTCGAGTCGTATTTTTGCAGTTTCTTCCA
AAACTTGTTTGCATGAAACGCCCAAAATCGGCATCTGAGCGAAGCGCTGTCCGTTCTGGA
ATGGCCCAACTACCAGGAGTTGGACAGTTTACATTAAGCCCATCAGCTCATCATCCACTA
TGTCCATCAGCTGATGATCGAACAACTACAATTCGAAATACTGCATCAAATGAGACGTCT
GCATATTATCCATTAAGTACTGATGCTCTACGAGCAATTGATGCAATTGAGTATATTACG
GAACATTTGAAAAGAGACGAGCAACATAAATCGTTCCGAGACGATTGGAAATATGTGGCA
ATGATAATCGATCGATTGCTGCTTTATGTATTTTTTGGAATAACTGTTGGAGGAACATGT
GGTATTCTGTTTTCCGCGCCTCACGTATTCCAGAGAATTGATCAACAAGAAATGTTGGAT
CGTCTCAAAGAGAAATACGATACAGCATCCAATATTCCCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF02931</identifier>
            <name>Neur_chan_LBD</name>
          </pfam>
          <pfam>
            <identifier>PF02932</identifier>
            <name>Neur_chan_memb</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>acetylcholine-gated channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuron projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal cell body</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synapse</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>acetylcholine-activated cation-selective channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cation transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>locomotion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurological system process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuromuscular synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of membrane potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of oviposition</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of pharyngeal pumping</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to nicotine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission, cholinergic</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>